Lawyers Lawyer Search News, Publications, Events News Publications Events Practices Industries Corporate Finance Restructuring and Reorganization Tax, Benefits, and Compensation Employment, Labor and OSHA Environmental International Litigation Intellectual Property Regulatory/Public Policy Rankings Rankings Search Offices Abu Dhabi Austin Beijing Dallas Dubai Hong Kong Houston London Moscow New York Palo Alto Riyadh Shanghai Tokyo Washington Careers Law Students Professional Development Public Interest Split Summer Program Judicial Clerkships Laterals London Recruitment Paralegals Administrative About V&E Introduction Pro Bono Community Diversity and Inclusion Women's Initiative		Search Entire Site Lawyers News, Publications, Events Practices Rankings Offices Careers About V&E Home > News, Publications, Events > Publications > Biologics Price Competition and Innovation Act of 2009  Publication Biologics Price Competition and Innovation Act of 2009  Presented at the V&E Continuing Legal Education Program, May 10, 2010 In 2009, Congress passed legislation relating to FDA approval of generic biologics as a rider on the Health Care Bill. As biological drug products are an increasingly important component of the U.S. health care market, this new legislation is of particular importance to both patent law and the health care industry. View and download the V&E Intellectual Property presentation given by partner Stephen Hash. This information is provided by Vinson & Elkins LLP for educational and informational purposes only and is not intended, nor should it be construed, as legal advice. << Back to Top Site Map    Contact Us    Extranet    Disclaimer & Legal Notice     ©1999-2012 Vinson & Elkins LLP		RSS